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Background: The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are two commonly used measures
of inflammation in rheumatoid arthritis (RA). As current RA treatment guidelines strongly emphasize early and
aggressive treatment aiming at fast remission, optimal measurement of inflammation becomes increasingly important.
Dependencies with age, sex, and body mass index have been shown for both inflammatory markers, yet it remains
unclear which inflammatory marker is affected least by these effects in patients with early RA.
Methods: Baseline data from 589 patients from the DREAM registry were used for analyses. Associations between the
inflammatory markers and age, sex, and BMI were evaluated first using univariate linear regression analyses. Next, it was
tested whether these associations were independent of a patient’s current disease activity as well as of each other
using multiple linear regression analyses with backward elimination. The strengths of the associations were compared
using standardized beta (β) coefficients. The multivariate analyses were repeated after 1 year.
Results: At baseline, both the ESR and CRP were univariately associated with age, sex, and BMI, although the
association with BMI disappeared in multivariate analyses. ESR and CRP levels significantly increased with age (β-ESR =
0.017, p < 0.001 and β-CRP = 0.009, p = 0.006), independent of the number of tender and swollen joints, general health,
and sex. For each decade of aging, ESR and CRP levels became 1.19 and 1.09 times higher, respectively. Furthermore,
women demonstrated average ESR levels that were 1.22 times higher than that of men (β = 0.198, p = 0.007), whereas
men had 1.20 times higher CRP levels (β = -0.182, p = 0.048). Effects were strongest on the ESR. BMI became significantly
associated with both inflammatory markers after 1 year, showing higher levels with increasing weight. Age continued
to be significantly associated, whereas sex remained only associated with the ESR level.
Conclusions: Age and sex are independently associated with the levels of both acute phase reactants in early RA,
emphasizing the need to take these external factors into account when interpreting disease activity measures.
BMI appears to become more relevant at later stages of the disease.
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Acute phase reactants are commonly used as a measure
of inflammation in rheumatoid arthritis (RA) and are
part of the provisional definition of RA remission as de-
fined by the ACR/EULAR [1], the ACR preliminary core
set of RA disease activity measures [2], and the 28-joint
Disease Activity Score (DAS28) [3]. Traditionally, the
erythrocyte sedimentation rate (ESR) has been the most
widely used marker of inflammation in RA. The ESR is
an indirect measure of inflammation, which reflects the
level of acute-phase plasma proteins in the blood (e.g. fi-
brinogen) because these cause the red blood cells to set-
tle more rapidly [4]. However, a number of limitations of
this inflammatory marker have become apparent over
the years. Although the test is relatively easy and inex-
pensive to perform, ESR levels respond slowly to inflam-
matory stimuli and, thus, to changes in disease activity.
Given the current emphasis on strict and aggressive
treatment strategies [5,6] that suppress RA disease activ-
ity as early, fast and complete as possible [7,8], this slow
response of the ESR levels is often considered a limita-
tion. Also, because the ESR is a non-specific acute phase
reactant of systemic inflammation, elevated levels are
not necessarily (solely) due to the inflammation of the
rheumatic disease. It has been shown that ESR levels can
be greatly influenced by, for instance, infections, malig-
nancies, abnormally shaped or sized red blood cells or
serum protein concentrations [9]. They also tend to be
higher in females than in males [10-15] and appear to
increase with age [10-17] and with body mass index
(BMI) [4,13,18]. Thus, even though the ESR is still
widely used in clinical research and practice because of
its familiarity, its simplicity, and the attention it received
over the years [9], these limitations may complicate the
use of the ESR in assessing RA disease activity.
In an attempt to overcome some of these limitations,
the C-reactive protein (CRP) has been suggested as an
alternative inflammatory marker of disease activity in
RA [19]. The CRP is a protein that is produced in the
liver as a reaction to certain biologic ligands that appear
when inflammation develops [4]. Many studies tend to
favor CRP over ESR in assessing RA inflammation [20],
as it is believed to give a better reflection of current dis-
ease activity than ESR because of its more rapid re-
sponse to increases or decreases in inflammatory stimuli
[4,9]. Another commonly supposed advantage of CRP is
its lower susceptibility to external confounding factors
like age and sex, compared to the ESR [4]. However, an
extensive number of studies have suggested that CRP
may exhibit similar dependencies on age [16,21-23], sex
[22-24], and BMI [4,18,21-23,25-27].
As current RA treatment guidelines strongly emphasize
early and aggressive treatment aiming at fast remission
[5,6], optimal measurement of inflammation in this patientgroup is becoming increasingly important. To date, how-
ever, it remains unclear which inflammatory marker is af-
fected most strongly by the external effects of age, sex,
and BMI in patients with early RA and with this study we
aim to provide more insight into these associations.Methods
Patients
Data were used from the remission induction cohort of
the Dutch Rheumatoid Arthritis Monitoring (DREAM)
registry [28]. This observational multicenter cohort in-
cluded patients that were newly and clinically diagnosed
with RA by a certified rheumatologist, who experienced
symptoms for less than a year and who were not in remis-
sion at the time of inclusion. Patients followed a treat-to-
target treatment protocol that aimed at a fast remission
(DAS28 < 2.6). This protocol has been described elsewhere
[28,29]. Only patients who had a valid baseline measure of
both the ESR and the CRP were included for analyses,
which resulted in the exclusion of 37 patients. Independent
t‐tests, Kruskal Wallis tests, and Chi‐Square tests showed
that the excluded patients did not differ from the other pa-
tients in any of the collected baseline measures (described
in the next paragraph). All patients were 18 years or older
and had not used DMARDs or prednisolone before. Pa-
tient recruitment took place from 2006 to 2012 and data
collection of included patients is still ongoing. Informed
consent was obtained from each patient. No ethical ap-
proval was required, as evaluated by the ethics committees
of the participating hospitals and in accordance with
Dutch law, since all data collected are part of daily clinical
practice.Measures
Baseline data were collected on several demographic, clin-
ical, and patient-reported measures. The patient’s age, sex,
anti-CCP positivity, and rheumatoid factor were registered,
BMI was calculated as the ratio of weight in kilograms and
the square of the height in meters, physical functioning
was assessed with the Health Assessment Questionnaire
(HAQ, score range 0-3, where higher values reflect worse
outcomes) [30], and physical and mental health status with
the Short Form Health Survey with 36 items (SF-36, score
range 0-100, where lower values reflect worse outcomes)
[31]. At each visit, disease activity was assessed by a
trained rheumatologist or nurse practitioner following a
standardized procedure using either the DAS28-ESR or
the DAS28-CRP, respectively [3,19]. The DAS28 is an
index measure including a 28-joint count of both tender-
ness and swelling (TJC28 and SJC28, score range 0-28), a
patient reported visual analog scale of general health (GH,
score range 0-100), and an inflammatory marker, which
can be either the ESR or the CRP.
Table 1 Characteristics of the study population at
inclusion
Characteristic Mean (SD) or Median (IQR)*
Sex (female) 362/589 (61.5%)
Age (years) 57.34 (14.20)
Symptom duration (weeks) 14.00 (8.00-26.00)
Body mass index (kg/m2) 26.59 (4.44)
Normal (N = 198) 22.64 (1.89)
Overweight (N = 209) 27.09 (1.35)
Obese (N = 97) 33.54 (3.23)
ESR (mm/hour) 21.00 (11.00-36.00)
CRP (mg/l) 7.00 (5.00-19.50)
28-Tender joint count 3.00 (0.00-7.00)
28-Swollen joint count 5.00 (2.00-9.00)
General health 44.55 (26.39)
DAS28-ESR 4.23 (1.51)
DAS28-CRP 4.00 (1.35)
SF36 – physical health 37.41 (9.32)
SF36 – mental health 48.13 (11.59)
HAQ 0.99 (0.72)
Anti-CCP positive 139/228 (61.0%)
Rheumatoid factor positive 285/520 (54.8%)
*The values for sex, RF and anti-CCP positivity are the number of patients/number
of patients assessed. DAS-28 = disease activity score for 28 joints, ESR = erythrocyte
sedimentation rate, CRP = C-Reactive Protein, SF36 = Short Form Health Survey with
36 items, HAQ=Health Assessment Questionnaire.
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BMI was divided into 3 categories (i.e. normal weight
(<25 kg/m2), overweight (25-30 kg/m2), and obese
(>30 kg/m2)) and the values of the ESR and CRP were
natural-log-transformed to normalize their distributions.
The associations between the inflammatory markers and
age, sex, and BMI were evaluated using univariate linear
regression analyses first (using p < 0.10 for significance).
Next, it was tested whether these associations were inde-
pendent of a patient’s current disease activity (as mea-
sured with the other core components of the DAS28) as
well as of each other by performing multiple linear re-
gression analyses with backward elimination. Possible
interaction terms of the remaining variables were tested
for significance. Standardized beta coefficients were used
to compare the strength of the relationships in the final
models. To evaluate whether the associations changed
over time, the multivariate analyses were repeated on
the 1-year’s data (i.e. data collected after 1 year of treat-
ment). All analyses were performed using SPSS, version
21.0. Statistical significance in the multivariate analyses
was defined as p < 0.05.
Results
Patients
A total sample of 589 early RA patients was included for
analyses. At inclusion, patients were not in remission as
characterized by a DAS28 score >2.6 (i.e. the cut-off point
for not being in remission), several tender and swollen
joints, and a diminished feeling of general and physical
health (Table 1). Patients were on average 57 years old, the
majority being female, and most had some degree of over-
weight (60.7% had a BMI ≥25 kg/m2).
Univariate analyses
Without controlling for possible confounding factors, both
ESR and CRP levels increased with age and tended to in-
crease with BMI (Table 2). Furthermore, women tended to
have higher ESR levels than men, whereas men tended to
have higher CRP levels.
Multivariate analyses
At baseline
After adjusting for the other core components of disease
activity that are included in the DAS28 (i.e. the TJC28,
SJC28, and GH), sex and age were still independently as-
sociated with both inflammatory markers, while BMI
was no longer related to a patient’s ESR or CRP level
(Table 3). Although the effects of age were slightly atten-
uated, the effects of sex were not and became even
stronger in the ESR model.
Thus, obese patients did not show significantly higher
levels of ESR or CRP (mean ± SD ESR: 29.34 ± 21.87,
CRP: 17.30 ± 22.06) than overweight (ESR: 26.28 ± 18.76,CRP: 18.14 ± 19.84) or normal weight patients (ESR:
26.70 ± 22.25, CRP: 16.97 ± 24.21). On the other hand,
ESR and CRP levels did significantly increase with age
(β-ESR = 0.017, p < 0.001 and β-CRP = 0.009, p = 0.006),
independent of the number of tender and swollen joints,
the patient-reported degree of general health, and the
patient’s sex. The unstandardized betas (0.017 vs. 0.009)
represent the change of the natural-log-transformed ESR
and CRP levels, respectively, for each year of aging.
Transformed back to their normal values, this means
that for each decade of aging the ESR and CRP levels be-
come 1.19 and 1.09 times higher, respectively. Further-
more, women demonstrated average ESR levels that
were 1.22 times higher than those of the men (β = 0.198,
p = 0.007), whereas men had 1.20 times higher CRP
levels (β = -0.182, p = 0.048). The effects of age and sex
were strongest in the ESR model, indicating that the
ESR is more sensitive to the effects of these external fac-
tors. Although there were no significant interactions be-
tween age and sex (interaction ESR model: p = 0.222 and
interaction CRP model: p = 0.665), differences in ESR
and CRP between male and female patients appeared to
gradually decrease with age (Table 4).
Table 2 Univariate associations of the inflammatory markers (ESR and CRP) with age, sex, and BMI at baseline
Univariate association* Unstandardized coefficient Standardized coefficient p-value
Beta (95% CI) Standard error Beta (95% CI)
ESR
Age 0.019 (0.014 - 0.024) 0.003 0.296 (0.219 – 0.373) <0.001
Female sex 0.136 (-0.018 - 0.290) 0.078 0.072 (-0.009 – 0.152) 0.083
Overweight 0.048 (-0.126 - 0.222) 0.088 0.026 (-0.067 – 0.118) 0.587
Obese 0.190 (-0.027 - 0.407) 0.110 0.081 (-0.011 – 0.173) 0.086
CRP
Age 0.013 (0.007-0.020) 0.003 0.164 (0.084 – 0.244) <0.001
Female sex -0.183 (-0.372 – 0.006) 0.096 -0.078 (-0.159 – 0.002) 0.057
Overweight 0.248 (0.035 – 0.462) 0.109 0.108 (0.015 – 0.200) 0.023
Obese 0.250 (-0.018 – 0.517) 0.136 0.086 (-0.006 – 0.179) 0.067
*Analyses were performed on the naturally log-transformed ESR and CRP values to normalize their distributions.
ESR = erythrocyte sedimentation rate, CRP = C-Reactive Protein, CI = confidence interval. The males and normal weight patients were used as reference categories.
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Interestingly, BMI did become significantly associated
with both the ESR and the CRP after 1 year (Table 5).
Heavier patients show higher ESR and CRP levels. Age
continued to be significantly associated, although this rela-
tionship was no longer linear but increased exponentially.
Sex, on the other hand, was still significantly associated
with ESR levels (showing higher levels in females), but was
no longer significantly associated with CRP (p = 0.855).
Discussion
In this study, age and sex were independently associated
with the levels of both acute phase reactants in early
RA, although the effects appeared to be strongest on the
ESR. These results emphasize the need to take these ex-
ternal factors into account when interpreting diseaseTable 3 Multivariate associations of the inflammatory marker
Variables* Unstandardized coefficient
Beta (95% CI) Standa
ESR model
TJC28 -0.012 (-0.028 – 0.003) 0
SJC28 0.044 (0.028 – 0.059) 0
General health 0.006 (0.003 – 0.009) 0
Female sex 0.198 (0.053 – 0.342) 0
Age 0.017 (0.012 – 0.022) 0
CRP model
TJC28 -0.001(-0.020 – 0.018) 0
SJC28 0.058 (0.039 – 0.077) 0
General health 0.008 (0.004 – 0.011) 0
Female sex -0.182 (-0.362 – -0.001) 0
Age 0.009 (0.002 – 0.015) 0
*ESR = erythrocyte sedimentation rate, CRP = C-Reactive Protein, TJC28 = tender join
interval. R2 ESR-model: 18.7%, R2 CRP model: 16.2%.activity in patients with early RA. Because the acute phase
reactants tend to increase with age, independent of other
core measures of disease activity, the disease activity of
older-aged patients might be overestimated. Also, ESR
values are more likely to be elevated in women than in
men, whereas the opposite appears to be the case for CRP.
Although no significant interactions were found be-
tween age and sex, the gradually decreasing differences
in ESR and CRP between male and female patients with
age are consistent with findings from Radovits et al.
[15]. Furthermore, the finding that the ESR tends to be
more elevated in women than in men is consistent with
the results of previous studies [11-15]. However, incon-
clusive results have been reported on sex differences in
CRP levels. Where Lee et al. [23] found CRP values to
be higher in males than in females, other studies haves (ESR and CRP) with age and sex at baseline (N = 589)
Standardized coefficient p-value
rd error Beta (95% CI)
.008 -0.075 (-0.168 – 0.018) 0.115
.008 0.256 (0.166 – 0.345) <0.001
.001 0.170 (0.089 – 0.250) <0.001
.073 0.104 (0.028 – 0.179) 0.007
.003 0.262 (0.186 – 0.337) <0.001
.010 -0.006 (-0.100 – 0.089) 0.908
.010 0.279 (0.188 – 0.370) <0.001
.002 0.180 (0.098 – 0.262) <0.001
.092 -0.078 (-0.155 – -0.001) 0.048
.003 0.108 (0.031 – 0.185) 0.006
t count in 28-joints, SJC28 = swollen joint count in 28-joints. CI = confidence
Table 4 ESR and CRP levels in men and women per age group
Men (N = 227) Women (N = 362)
Variable* Median (IQR) Variable* Median (IQR)
ESR ESR
Age group Age group
<55 years (n = 70) 11.00 (4.75-29.00) <55 years (n = 161) 15.00 (8.00-29.00)
55 - 65 years (n = 80) 17.50 (10.00-33.00) 55 - 65 years (n = 95) 25.00 (12.00-37.00)
>65 years (n = 77) 31.00 (17.50-41.50) >65 years (n = 106) 27.00 (17.75-42.00)
CRP CRP
Age group Age group
<55 years (n = 70) 6.50 (5.00-17.50) <55 years (n = 161) 5.00 (5.00-13.00)
55 - 65 years (n = 80) 8.50 (5.00-24.00) 55 - 65 years (n = 95) 5.00 (5.00-18.00)
>65 years (n = 77) 11.00 (5.00-26.50) >65 years (n = 106) 10.00 (5.00-24.25)
*ESR = erythrocyte sedimentation rate, CRP = C-Reactive Protein.
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population samples (including genetic variations, diet, and
lifestyle) [13,23] and the use of different measurement
methods for determining the CRP levels may possibly ex-
plain these diverse results. Since the patient population of
this present study is probably more similar to the France
and US populations of Piéroni et al. [22] and Lakoski et al.
[24], respectively, than the Korean population examined
by Lee et al. [23], it was expected to find higher CRP levels
in females as well. Nevertheless, the exact underlyingTable 5 Multivariate associations of the inflammatory marker
(N = 365)
Variables* Unstandardized coefficient
Beta (95% CI) Stand
ESR model
TJC28 -0.024 (-0.056 – 0.008) 0
SJC28 0.014 (-0.030 – 0.058) 0
General health 0.004 (0.000 – 0.008) 0
Female sex 0.370 (0.187 – 0.552) 0
Age: 55-65 years 0.151 (-0.055 – 0.356) 0
Age: >65 years 0.570 (0.363 – 0.777) 0
Overweight -0.349 (-0.581 – -0.117) 0
Normal weight -0.283 (-0.520 – -0.045) 0
CRP model#
TJC28 -0.014 (-0.047 – 0.019) 0
SJC28 -0.002 (-0.047 – 0.043) 0
General health 0.007 (0.002 – 0.011) 0
Age: 55-65 years 0.073 (-0.137 – 0.283) 0
Age: >65 years 0.292 (0.081 – 0.504) 0
Overweight -0.257 (-0.494 – -0.020) 0
Normal weight -0.328 (-0.571 – -0.085) 0
*ESR = erythrocyte sedimentation rate, CRP = C-Reactive Protein, TJC28 = tender join
interval. R2 ESR-model: 15.6%, R2 CRP model: 6.9%.
#After 1 year, sex was no longer significantly associated with CRP levels (p = 0.855).mechanisms behind these dependencies remain unknown
and all these previous studies were conducted in healthy
community populations instead of in samples with active
disease. Perhaps the underlying processes of early RA, cer-
tain lifestyle differences, the higher prevalence of obesity
in the women, hormonal factors, or differences in meta-
bolic risk factor [14,15,23] might (partly) explain the
higher baseline CRP levels in men in this study or the
diminishing association between sex and CRP after 1 year.
However, this warrants further research.s (ESR and CRP) with age, sex, and BMI after 1 year
Standardized coefficient p-value
ard error Beta (95% CI)
.016 -0.088 (-0.206 – 0.031) 0.147
.022 0.035 (-0.074 – 0.144) 0.527
.002 0.103 (-0.012 – 0.219) 0.080
.093 0.213 (0.108 – 0.317) <0.001
.105 0.084 (-0.031 – 0.198) 0.151
.105 0.320 (0.203 – 0.436) <0.001
.118 -0.207 (-0.345 – -0.069) 0.003
.121 -0.164 (-0.302 – -0.026) 0.020
.017 -0.052 (-0.174 – 0.070) 0.405
.023 -0.006 (-0.119 – 0.107) 0.917
.002 0.179 (0.060 – 0.297) 0.003
.107 0.041 (-0.077 – 0.159) 0.495
.107 0.165 (0.046 – 0.284) 0.007
.120 -0.154 (-0.296 - -0.012) 0.033
.124 -0.192 (-0.335 - -0.050) 0.008
t count in 28-joints, SJC28 = swollen joint count in 28-joints. CI = confidence
Consequently, this factor is no longer included in the CRP model.
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cluded that age was unrelated to CRP [15], Ranganath
et al. [16] did find significant associations of age with both
inflammatory markers in early RA. Likewise, the increas-
ing inflammatory marker levels with age are consistent
with a wide variety of other studies [11-14,16,17,21-23].
Like sex differences, the increasing ESR and CRP levels
with age might be explained by certain immunological
or hematological changes and, for instance, hormonal
changes in women who reach the menopause [14,15,17].
Furthermore, it has been suggested that RA in older aged
people might be more severe than in the young [15]. Sup-
plementary post-hoc analyses did indeed show signifi-
cantly more swollen joints, higher inflammatory values,
and a more active disease according to the DAS28-ESR
score in the two highest age groups (55-65 and >65 years
old) compared to the youngest group (<55 years old).
In contrast to previous studies, no independent associ-
ation between BMI and acute phase reactants was found
at baseline. Perhaps the proportion of obese patients in
this study was too small to detect these effects (15.2% of
the men and 21.7% of the women). Likewise, only 8 pa-
tients were underweighted with a BMI <18.5 kg/m2 and
only 4 patients had morbid overweight with a BMI
>40 kg/m2. However, BMI did become significantly associ-
ated with ESR and CRP after 1 year, which might indicate
its possible importance at later stages of the disease. It has
been suggested that higher BMI levels (i.e. overweight or
obese) promote a higher secretion of interleukin-6 (IL-6),
a pro-inflammatory cytokine, regulating the secretion of
the acute phase reactants [21-23,26]. A factor which might
play a role in this association is the patient’s physical activ-
ity [23,25] given its potential positive effects on the body
mass index. Vigorous physical activity might prevent the
accumulation of abdominal fat which, consequently, may
result in a reduced IL-6 production and lower levels of the
acute phase reactants [23,32]. Taking this one step further,
this might also explain why the relation with sex dissipated
in the CRP model. If men were more active than women,
this might have caused their CRP levels to drop signifi-
cantly more, reducing any sex effects [32]. However, a
thorough understanding of the relationship between phys-
ical activity and BMI or the acute phase reactants remains
uncertain and warrants further research.
A possible limitation of the current study might be the
exclusion of other potential confounding variables, such
as certain lifestyle factors (e.g. smoking, physical activ-
ity), dietary patterns, or medication use (e.g. estrogen,
steroids, or NSAIDs) [21-23,25,33]. To study the effects
of these variables, further research is needed. Till then,
the results of this study should be interpreted with cau-
tion. Furthermore, it is a notable finding that the acute
phase reactants as well as the number of affected joints
were relatively low in the recruited patient sample, eventhough they were not in remission (DAS28 > 2.6). Yet
this is not very surprising given the early stage of their
disease. The disease might still be developing when the
patient comes to visit the clinic, but enough symptoms
may be present for classification and for inclusion in the
cohort. Still, this could limit the generalizability of the
results towards other populations with more active dis-
ease. Finally, even though the proportion of females in
this study (61%) might seem relatively low and the aver-
age age of the patients (57 years old) might seem rela-
tively high for the early onset of RA, these numbers do
correspond to previous results of (Dutch) early RA pop-
ulations [34-36]. Nevertheless, the results of this study
might not be generalizable to populations with a differ-
ent composition.
Conclusions
In conclusion, these results suggest that caution should
be taken when assessing disease activity in early RA
because the ESR and CRP levels are both influenced by
non-inflammatory factors like age and sex. Consequently,
disease activity might be either overestimated or underesti-
mated. Since the CRP appeared to be less sensitive to exter-
nal factors this might be designated as the preferred
measure, which is consistent with results from Radovits
et al. [15] and Crowson et al. [20]. However, one should
keep in mind that there might be other confounding factors
that were not included in this study (e.g. NSAIDs or corti-
costeroids), but which may affect the inflammatory markers
as well, potentially making the use of the ESR equally ac-
ceptable. It could also be argued to develop modified
DAS28 scores, including an adaptation for age and sex be-
cause these are two risk factors that cannot be modified.
Miller et al. [11] already proposed a simple formula for cal-
culating age-adjusted ESR values. However, this was several
decades ago, so supplementary research on the possible
incorporation of sex and age adjustments in the DAS28 for-
mula is recommended. Another solution might be to spe-
cify age and sex specific thresholds of current disease
activity scores in order to make them comparable across
patient subgroups of different age and sex. Yet to determine
the values of such thresholds, further research is required.
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